A projection of benefits due to fecal occult blood test for colorectal cancer

Cancer Epidemiology

Volumn 33, Issue 3-4, 2009, Pages 212-215

  Wu, Dongfeng ^a   Erwin, Diane ^b   Rosner, Gary L ^c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer screening; Fecal occult blood test (FOBT); Lead time; Sensitivity; Sojourn time; Transition probability

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; EARLY DIAGNOSIS; FEMALE; HUMAN; LEAD TIME; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; PARAMETER; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; SCREENING TIME INTERVAL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; TIME;

ADULT; AGED; AGED, 80 AND OVER; BAYES THEOREM; COLORECTAL NEOPLASMS; FEMALE; HEALTH POLICY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SEX FACTORS; TIME FACTORS;

EID: 70349754152     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.08.001     Document Type: Article

References (16)

1. Wu D., Rosner G.L., and Broemeling L.D. Bayesian inference for the lead time in periodic cancer screening. Biometrics 63 3 (2007) 873-880 10.1111/j.1541-0420.2006.00732.x
2. Cancer facts and figures. American Cancer Society; 2008. http://www.cancer.org/downloads/stt/2008cafffinalsecured.pdf.
3. SEER Fast Stats Results, NIH. http://seer.cancer.gov/statfacts/html/colorect.html.
4. Anderson W.F., Guyton K.A., Hiatt R.A., Vernon S.W., Levin B., and Hawk E. Colorectal cancer screening for person at average risk. J Natl Cancer Inst 94 (2002) 1126-1133
5. Church T.R. Offering patients colorectal cancer screening. J Natl Cancer Inst 97 (2005) 328-329
6. Wu D., Erwin D., and Rosner G.L. Estimating key parameters in FOBT screening for colorectal cancer. Cancer Causes Control 20 (2009) 41-46 10.1007/s10552-008-9215-9
7. Wu D., Rosner G.L., and Broemeling L.D. MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening. Biometrics 61 4 (2005) 1056-1063 10.1111/j.1541-0420.20005.00361.x
8. Mandel J.S., Church T.R., Ederer F., and Bond J.H. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (1999) 434-437 10.1093/jnci/91.5.434
9. Launoy G., Smith T.C., Duffy S.W., and Bouvier V. Colorectal cancer massscreening: estimation of fecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int. J. Cancer 73 (1997) 220-224
10. Prevost T.C., Launoy G., Duffy S., and Chen H.H. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches. Am J Epidemiol 148 (1998) 609-619
11. Walter S.D., and Day N.E. Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol 118 (1983) 856-886
12. Prorok P.C. Bounded recurrence times and lead time in the design of a repetitive screening program. J Appl Prob 19 (1982) 10-19
13. Straatman H., Peer P., and Verbeek A. Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics 53 (1997) 217-229
14. Kafadar K., and Prorok P.C. Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials. Stat Med 22 (2003) 83-111
15. Hewitson P., Glasziou P., Watson E., Towler B., and Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103 6 (2008) 1541-1549
16. Launoy G., and Berchi C. Advantage of immunochemical fecal occult blood test in screening for colorectal cancer. Bull Cancer 9 (2005) 885-890